您好,歡迎光臨寶科生物
請登錄  免費注冊 | 會(huì )員中心
您現在的位置: 首頁(yè) > 新聞資訊 > 精品推薦 > 體外診斷
新聞資訊
News information
一抗專(zhuān)題 免疫組化 天然免疫 體外診斷

體外診斷

新冠研究蛋白、抗體等試劑庫

發(fā)布時(shí)間:2022-06-15 16:16:45 點(diǎn)擊:2645

新冠研究蛋白、抗體等試劑庫

由新冠病毒引起的新冠肺炎疫情影響了全球的醫療衛生系統以及經(jīng)濟,同時(shí)不斷突變的新毒株對新冠疫苗、治療藥物以及診斷都帶來(lái)了巨大的挑戰。義翹神州一直密切關(guān)注新冠病毒的進(jìn)化情況,已保證第一時(shí)間研發(fā)出新冠病毒相關(guān)的蛋白、抗體等試劑。目前,我們的蛋白、抗體試劑以廣泛被全球科學(xué)家們用于新冠相關(guān)的各方面的研究,已助力正式發(fā)表900多篇科研論文。除此之外,我們的試劑產(chǎn)品也被用于免疫檢測試劑的核心原料用于其開(kāi)發(fā)上市。我們已開(kāi)發(fā)了擁有200+新冠突變體蛋白的突變體蛋白庫,覆蓋了VOC, VOI等突變位點(diǎn)。這些突變體蛋白也已經(jīng)被研究著(zhù)們用于新冠病毒免疫逃逸等相關(guān)研究。

重組新冠抗原

  • 重組Spike蛋白

  • 重組N蛋白

  • 重組突變體蛋白庫

  • 酶類(lèi),NSP蛋白等

  • 宿主受體ACE2蛋白

SARS-CoV-2 Antigen Detection 

SARS-CoV-2 Spike 蛋白推薦

貨號抗原表達宿主標簽
40591-V08HS1HEK293 CellsHis
40590-V08BS2Baculovirus-Insect CellsHis
40592-V05HRBDHEK293 CellsmFc
40592-V08BRBDBaculovirus-Insect CellsHis
40592-V08HRBDHEK293 CellsHis

更多SARS-CoV-2 Spike 蛋白

貨號抗原表達宿主標簽
40589-V08H4S1+S2 ECDHEK293 CellsHis
40591-V02HS1HEK293 CellsFc
40591-V05H1S1HEK293 CellsmFc
40591-V08B1S1Baculovirus-Insect CellsHis
40591-V08H-B BiotinylatedS1HEK293 CellsHis
40591-V27H-B BiotinylatedS1HEK293 CellsAVI & His
40591-V41HS1 NTDHEK293 CellsFc & AVI
40591-V41H-B BiotinylatedS1 NTDHEK293 CellsFc & AVI
40591-V49HS1 NTDHEK293 CellsHis & AVI
40591-V49H-B BiotinylatedS1 NTDHEK293 CellsHis & AVI
40589-V08B1S1+S2 ECDBaculovirus-Insect CellsHis
40589-V08B1-B BiotinylatedS1+S2 ECDBaculovirus-Insect CellsHis
40589-V27B-B BiotinylatedS1+S2 ECDBaculovirus-Insect CellsAVI & His
40590-V02HS2HEK293 CellsFc
40590-V05BS2Baculovirus-Insect CellsmFc
40590-V08B-B BiotinylatedS2Baculovirus-Insect CellsHis
40590-V08H1S2HEK293 CellsHis
40592-V02HRBDHEK293 CellsFc
40592-V08B-B BiotinylatedRBDBaculovirus-Insect CellsHis
40592-V08H-B BiotinylatedRBDHEK293 CellsHis
40592-V27B-B BiotinylatedRBDBaculovirus-Insect CellsAVI & His
40592-V27H-B BiotinylatedRBDHEK293 CellsAVI & His
40592-V31HRBDHEK293 CellsrFc
40592-VNAHRBDHEK293 Cells

新冠抗體試劑

義翹神州開(kāi)發(fā)生產(chǎn)了針對新冠病毒不同抗原抗體試劑,特異性、中和效應以及多種應用均經(jīng)過(guò)驗證。

高親和力
Binding affinity has been validated by BLI assay.

  • BLI: KD=0.006 nM

    Anti-Spike Rabbit MAb (cat#:40592-R001)

  • BLI: KD=0.01 nM

    Anti-N Rabbit MAb (cat#:40143-R040)

  • 高特異性
    ELISA assay has been taken to validate the cross-reactivity with Spike antigens from different Human Coronaviruses.

    No cross-reactivity with SARS-CoV, MERS-CoV, HKU1, 229E, NL63, and OC43.

  • 中和效應
    The anti-RBD neutralizing antibody could effectively block the binding between recombinant spike RBD and ACE2 protein, and inhibit the infection of spike pseudovirus to ACE2 overexpressed HEK293T cells.

    Anti-Spike RBD Mouse MAb (cat#: 40592-MM57)



試劑盒采用雙抗夾心ELISA法,可以快速定量檢測N蛋白和S蛋白。試劑盒中使用的抗體均為義翹神州自主研發(fā)生產(chǎn)的單克隆抗體,已實(shí)現大量生產(chǎn)且可保證批次間穩定性。其中,S試劑盒經(jīng)過(guò)重組蛋白和假病毒檢測雙重驗證。

SARS-CoV-2 N Detection Kit
(KIT40588)

N 蛋白檢測試劑盒(Kit40588)

Spike 蛋白檢測試劑盒(Kit40591)

更多詳情:新冠病毒抗原蛋白檢測試劑盒
? 新冠病毒抑制劑篩選試劑盒
? 新冠病毒抗體滴度檢測試劑盒

新冠試劑發(fā)表文獻

截止到4月30日,已有近500篇正式發(fā)表的文章以及120篇預發(fā)表文章引用了義翹神州開(kāi)發(fā)的新冠相關(guān)科研試劑。

題目期刊作者年份
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunityCellThomson, E,et al.2021
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infectionCellBrouwer, PJM,et al.2021
The antigenic anatomy of SARS-CoV-2 receptor binding domainCellDejnirattisai, W,et al.2021
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infectionCellMills, R,et al.2021
COVID-19 immune features revealed by a large-scale single cell transcriptome atlasCellRen, X,et al.2021
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytiaCellAsarnow, D,et al.2021
Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\' B cellsCellCao, Y,et al.2020
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid AntibodiesCellWrapp, Daniel,et al.2020
Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and TreatmentCellSun, J,et al.2020
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2CellWang, H,et al.2020
A universal design of betacoronavirus vaccines against COVID-19, MERS and SARSCellDai, L,et al.2020
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and AntigenicityCellLi, Q,et al.2020
A thermostable mRNA vaccine against COVID-19CellZhang, N,et al.2020
High potency of a bivalent human VH domain in SARS-CoV-2 animal modelsCellLi, W,et al.2020
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCellPiccoli, L,et al.2020
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein VariantCellYurkovetskiy, L,et al.2020
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing StrategyCellDu, S,et al.2020
Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19CellMeckiff, B,et al.2020
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody ProductionCellChen, Y,et al.2020
Compromised humoral functional evolution tracks with SARS-CoV-2 mortalityCellZohar, T,et al.2020
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2CellHassan, AO,et al.2020
Compromised SARS-CoV-2-specific placental antibody transferCellAtyeo, C,et al.2020

2019新型冠狀病毒,即"SARS-CoV-2 (2019-nCoV)",因2019年武漢病毒性肺炎病例而被發(fā)現,和2003年的 SARS冠狀病毒以及2012年的MERS冠狀病毒同屬于冠狀病毒科β屬。

冠狀病毒基因組依次編碼棘突蛋白(spike protein)、包膜蛋白(Envelope protein)、膜蛋白(Membrane protein)和核衣殼蛋白(Nucleocapsid)。

棘突蛋白(spike protein) 是冠狀病毒最重要的表面膜蛋白,含有兩個(gè)亞基(subunit), S1和S2。其中S1主要包含有受體結合區(receptorbinding domain, RBD),負責識別細胞的受體。S2含有膜融合過(guò)程所需的基本元件。

Spike 蛋白承擔病毒與宿主細胞膜受體結合及膜融合功能,是宿主中和抗體的重要作用位點(diǎn)以及疫苗設計的關(guān)鍵靶點(diǎn)。SARS-CoV-2 (2019-nCoV) 的Spike蛋白與人ACE2互作來(lái)感染人的呼吸道上皮細胞。

核衣殼蛋白是冠狀病毒中含量最豐富的蛋白。在病毒體組裝過(guò)程中,N蛋白與病毒RNA結合并導致螺旋核衣殼的形成。核衣殼蛋白是一種高度免疫原性的磷蛋白,與病毒基因組復制和調節細胞信號通路有關(guān)。由于N蛋白的序列保守性和強大的免疫原性,N蛋白常被作為冠狀病毒診斷檢測工具

義翹神州于1月22日全球首發(fā)新冠病毒(SARS-CoV-2)重要靶點(diǎn)Spike RBD重組蛋白。為了更好的支持新冠肺炎的研究,義翹神州開(kāi)發(fā)生產(chǎn)了數百種新冠病毒(SARS-CoV-2)相關(guān)科研試劑,包括抗原蛋白(N蛋白、Spike全長(cháng)胞外域、 Spike S1、Spike S2、Spike RBD, Plpro, MTase, NSP3, NSP8,NSP9)、單抗、抗原蛋白檢測試劑盒、抑制劑篩選試劑盒、抗體滴度檢測試劑盒以及即用型表達基因。這些科研試劑已被全球數百家研究機構用于疫苗和治療性抗體開(kāi)發(fā)。義翹神州還可以提供新冠假病毒中和檢測服務(wù),可用于篩選出具有中和活性的抗體或血清,支持藥物研發(fā)在細胞水平上的評估。

SARS-CoV-2 (2019-nCoV)抗原試劑產(chǎn)品列表

 


引用文獻

? Xintian Xu.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.SCIENCE CHINA Life Sciences.2020
? Bo Diao, Zeqing Feng.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv preprint


沒(méi)有了
人類(lèi)冠狀病毒相關(guān)試劑